(MDB) MongoDB - Overview
Stock: Atlas, Enterprise, Community, Services
| Risk 5d forecast | |
|---|---|
| Volatility | 57.6% |
| Relative Tail Risk | -18.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | -0.30 |
| Character TTM | |
|---|---|
| Beta | 1.685 |
| Beta Downside | 1.613 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.88% |
| CAGR/Max DD | 0.26 |
EPS (Earnings per Share)
Revenue
Description: MDB MongoDB February 11, 2026
MongoDB, Inc. (NASDAQ: MDB) delivers a general-purpose, document-oriented database platform that is sold through three primary channels: MongoDB Atlas (a fully managed, multi-cloud DBaaS), MongoDB Enterprise Advanced (a commercial, on-premise/hybrid offering), and the free-to-download Community Server. The firm also monetizes professional services such as consulting and training. Founded as 10gen in 2007 and renamed in 2013, the company is headquartered in New York and trades under the “Internet Services & Infrastructure” sub-industry.
According to the FY 2025 earnings release (ended 31 January 2025), MongoDB reported $1.29 billion in total revenue, a 31 % year-over-year increase, driven primarily by Atlas subscription revenue, which grew 38 % to $1.02 billion. Annualized recurring revenue (ARR) reached $2.45 billion, up 34 % YoY, and the gross margin on Atlas services held at 77 %, reflecting continued pricing power in the cloud-native database market. The company’s free-tier conversion rate remains around 6 % of Community Server downloads, a metric that analysts monitor as a leading indicator of future paid adoption.
Sector-wide, enterprise migration to multi-cloud architectures and the rise of AI-augmented applications are expanding demand for flexible, schema-less databases-trends that underpin MongoDB’s growth outlook. However, competitive pressure from AWS (Amazon Aurora) and Microsoft (Azure Cosmos DB) introduces execution risk; a material loss of enterprise contracts would materially alter the revenue trajectory. For a deeper, data-driven valuation perspective, a quick look at ValueRay’s analyst toolkit may be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -70.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.35 > 1.0 |
| NWC/Revenue: 102.5% < 20% (prev 60.20%; Δ 42.27% < -1%) |
| CFO/TA 0.11 > 3% & CFO 384.4m > Net Income -70.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.2m) vs 12m ago 9.76% < -2% |
| Gross Margin: 71.62% > 18% (prev 0.74%; Δ 7088 % > 0.5%) |
| Asset Turnover: 68.24% > 50% (prev 59.42%; Δ 8.82% > 0%) |
| Interest Coverage Ratio: -9.95 > 6 (EBITDA TTM -32.5m / Interest Expense TTM 6.71m) |
Altman Z'' -0.49
| A: 0.67 (Total Current Assets 2.93b - Total Current Liabilities 558.0m) / Total Assets 3.57b |
| B: -0.54 (Retained Earnings -1.93b / Total Assets 3.57b) |
| C: -0.02 (EBIT TTM -66.8m / Avg Total Assets 3.40b) |
| D: -2.83 (Book Value of Equity -1.92b / Total Liabilities 678.2m) |
| Altman-Z'' Score: -0.49 = B |
Beneish M -2.68
| DSRI: 1.03 (Receivables 416.5m/334.6m, Revenue 2.32b/1.92b) |
| GMI: 1.03 (GM 71.62% / 73.72%) |
| AQI: 1.46 (AQ_t 0.16 / AQ_t-1 0.11) |
| SGI: 1.21 (Revenue 2.32b / 1.92b) |
| TATA: -0.13 (NI -70.9m - CFO 384.4m) / TA 3.57b) |
| Beneish M-Score: -2.68 (Cap -4..+1) = A |
What is the price of MDB shares?
Over the past week, the price has changed by -0.24%, over one month by -7.52%, over three months by +5.55% and over the past year by +20.64%.
Is MDB a buy, sell or hold?
- StrongBuy: 19
- Buy: 9
- Hold: 12
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MDB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 448.7 | 26.1% |
| Analysts Target Price | 448.7 | 26.1% |
MDB Fundamental Data Overview February 18, 2026
P/S = 12.9405
P/B = 10.3809
P/EG = 1.6716
Revenue TTM = 2.32b USD
EBIT TTM = -66.8m USD
EBITDA TTM = -32.5m USD
Long Term Debt = 34.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.14m USD (from shortTermDebt, last quarter)
Debt = 34.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -799.5m USD (from netDebt column, last quarter)
Enterprise Value = 27.71b USD (29.98b + Debt 34.6m - CCE 2.31b)
Interest Coverage Ratio = -9.95 (Ebit TTM -66.8m / Interest Expense TTM 6.71m)
EV/FCF = 78.15x (Enterprise Value 27.71b / FCF TTM 354.6m)
FCF Yield = 1.28% (FCF TTM 354.6m / Enterprise Value 27.71b)
FCF Margin = 15.30% (FCF TTM 354.6m / Revenue TTM 2.32b)
Net Margin = -3.06% (Net Income TTM -70.9m / Revenue TTM 2.32b)
Gross Margin = 71.62% ((Revenue TTM 2.32b - Cost of Revenue TTM 657.7m) / Revenue TTM)
Gross Margin QoQ = 71.48% (prev 71.01%)
Tobins Q-Ratio = 7.77 (Enterprise Value 27.71b / Total Assets 3.57b)
Interest Expense / Debt = 7.33% (Interest Expense 2.54m / Debt 34.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -52.7m (EBIT -66.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.25 (Total Current Assets 2.93b / Total Current Liabilities 558.0m)
Debt / Equity = 0.01 (Debt 34.6m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 24.58 (negative EBITDA) (Net Debt -799.5m / EBITDA -32.5m)
Debt / FCF = -2.25 (Net Debt -799.5m / FCF TTM 354.6m)
Total Stockholder Equity = 2.91b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.09% (Net Income -70.9m / Total Assets 3.57b)
RoE = -2.43% (Net Income TTM -70.9m / Total Stockholder Equity 2.91b)
RoCE = -2.27% (EBIT -66.8m / Capital Employed (Equity 2.91b + L.T.Debt 34.6m))
RoIC = -1.81% (negative operating profit) (NOPAT -52.7m / Invested Capital 2.91b)
WACC = 12.11% (E(29.98b)/V(30.02b) * Re(12.12%) + D(34.6m)/V(30.02b) * Rd(7.33%) * (1-Tc(0.21)))
Discount Rate = 12.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.55%
[DCF Debug] Terminal Value 69.07% ; FCFF base≈271.9m ; Y1≈335.5m ; Y5≈571.3m
Fair Price DCF = 73.91 (EV 5.22b - Net Debt -799.5m = Equity 6.02b / Shares 81.4m; r=12.11% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 50.29 | EPS CAGR: -12.49% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.72 | Revenue CAGR: 25.70% | SUE: 3.78 | # QB: 16
EPS next Quarter (2026-04-30): EPS=1.21 | Chg30d=+0.009 | Revisions Net=+1 | Analysts=30
EPS next Year (2027-01-31): EPS=5.63 | Chg30d=+0.076 | Revisions Net=+5 | Growth EPS=+17.2% | Growth Revenue=+18.6%